BridgeBio Oncology Therapeutics (BBOT)
Aaron Chan is an accomplished legal professional with extensive experience in corporate law, currently serving as the VP Head of Legal at BridgeBio Oncology Therapeutics since December 2024. Prior roles at BridgeBio included Assistant General Counsel and Senior Corporate Counsel, where responsibilities encompassed corporate governance, mergers, and acquisitions. Prior to joining BridgeBio, Aaron worked at Goodwin as an Associate, focusing on venture financings and securities transactions, and also held associate positions at Norton Rose Fulbright and Wilson Sonsini Goodrich and Rosati, dealing with various corporate law matters. Additionally, Aaron's background includes a role as Managing Editor for DestinationEats.com and as a Law Clerk at the Wikimedia Foundation. Aaron holds a BA in English and Accounting from UCLA and earned a law degree from Columbia Law School.
BridgeBio Oncology Therapeutics (BBOT)
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BridgeBio Oncology Therapeutics completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.